Activity and tolerance of XL647 in NSCLC patients with acquired resistance to EGFR-TKIs: Preliminary results of a phase II trial

8028 Background: XL647 is an orally bioavailable small molecule inhibitor of RTKs (EGFR, HER2, and VEGFR2) involved in tumor growth, angiogenesis, and metastasis. First-generation EGFR TKIs are act...